Phân tích

From master data and batch lifecycle to validation, change control and system-of-record ownership: why pharmaceutical ERP is harder than generic ERP, where implementations fail, and how a GxP-ready operating model becomes the foundation automation and AI actually need.

Từ quyết định thị trường và danh mục sản phẩm đến nhà thuốc và cảnh giác dược — tự động hoá theo quy tắc đã làm được gì, AI thêm giá trị ở đâu, và những quyết định nào phải thuộc về người chịu trách nhiệm.

South Korean pharmaceutical distributors announce order cut‑off dates of Sep 21‑23 before the Chuseok holiday, with shipments resuming on Sep 28.

Summer pharmacy OTC sales in South Korea displayed mixed movements, with acne drug Azelia rising sharply into the top‑10, while vitamin brands showed varied growth.

GSK reports its acne treatment Duac Gel 5% remains out of stock with no confirmed resupply timeline, urging pharmacies to monitor inventory.

Mounjaro drove over 30% growth in Korea's obesity treatment market in two months, while Wegovy sales fell for two consecutive months, dropping to fifth place.

Pharmacies report stockouts of pediatric oseltamivir suspension powder as influenza cases surge; some manufacturers still hold inventory, but supply pressure is rising.

Galderma Korea presented a new aesthetic portfolio—including fillers, biostimulators and skincare—at the GAIN RESTAGE event in Seoul, targeting natural, personalized results.

BaroPharm's Pharmacy Beauty Zone reaches 200 outlets within a month, targeting 1,000 pharmacies nationwide by year‑end.

Musinsa Beauty and the Onnuri pharmacy chain opened their first joint offline store in Hongdae, merging K‑beauty products with pharmacy‑grade cosmetics and skin‑care medicines.

Samsung Biologics announced a new CMO contract worth about KRW 3.5 trillion (~US$262 million) with a European pharmaceutical company, running until Dec 31 2033.

Jongkundang is working to secure reimbursement for its domestically developed GI medication Zitec, with the National Health Insurance Service evaluating its clinical usefulness, industrial value, alternative drug pricing, and fiscal impact.